Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Rui WangLongbang Chen

Abstract

FBLN-3 has been identified as an antagonist of angiogenesis which modulates cell morphology, growth, adhesion, and motility. In the present study, we investigated the promoter methylation status of FBLN-3 gene in non-small cell lung carcinoma (NSCLC) by methylation-specific PCR and analyzed its correlation with clinicopathological factors. The methylation of FBLN-3 gene promoter was detected in 28 of 65 (43.1%) NSCLC tissue samples and 6 of 65 (9.2%) corresponding non-tumor tissue samples (P<0.05). The methylation of FBLN-3 gene promoter led to the loss of FBLN-3 gene expression in NSCLC. Additionally, FBLN-3 promoter methylation was observed to be correlated with relative poor differentiation, advanced pathological stage and lymph node metastasis of NSCLC patients (P=0.017, 0.0057 or 0.002, respectively), but not with gender, age, histological type, and smoking condition (P>0.05). These results indicated that the loss of FBLN-3 gene induced by promoter methylation might play important roles in the progression of NSCLC and FBLN-3 promoter methylation might be a promising biomarker for early detection of NSCLC.

References

Mar 24, 2000·Trends in Genetics : TIG·S B Baylin, J G Herman
Jun 28, 2002·Cancer Cell·John D MinnaAdi F Gazdar
Aug 3, 2002·Oncogene·Jeffrey A TsouIte A Laird-Offringa
Aug 23, 2002·Seminars in Cancer Biology·Stephen B Baylin
Jun 5, 2003·Nature Reviews. Molecular Cell Biology·Rupert TimplMon-Li Chu
Nov 25, 2003·The New England Journal of Medicine·James G Herman, Stephen B Baylin
Sep 3, 2004·Nature Reviews. Cancer·Steven A Belinsky
Nov 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Partha M Das, Rakesh Singal
Jun 18, 2005·Trends in Molecular Medicine·William M GallagherLinda C Whelan
Mar 4, 2006·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Apr 26, 2007·The American Journal of Pathology·Chun-Hui YiMichael A Hollingsworth
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wen YueLin Zhang
Oct 12, 2007·The Prostate·Agnes WlazlinskiWolfgang A Schulz
Feb 4, 2009·Cellular and Molecular Life Sciences : CMLS·S de VegaY Yamada

❮ Previous
Next ❯

Citations

Jul 29, 2011·Pathology Oncology Research : POR·Zhu WangJiandong Tong
Dec 19, 2013·Genome Biology·Marcus RennerGunhild Mechtersheimer
Aug 12, 2015·British Journal of Cancer·Michaela B KirschnerGlen Reid
Apr 21, 2016·Journal of Cancer Research and Clinical Oncology·Kazuhiro YoshidaToshiyoshi Fujiwara
Jun 16, 2016·Cell Biology and Toxicology·Lianmin BaoXiangdong Wang
Jan 10, 2017·Journal of Clinical Medicine·Brunella CostanzaAndrei Turtoi
Apr 11, 2017·Environmental Research·Venerando RapisardaCarla Loreto
Jan 14, 2017·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Hao ShenMin Zhu
Jan 12, 2019·World Journal of Stem Cells·Saifun NaharJiro Fujita
Sep 12, 2020·Biomolecules·Imogen LivingstoneAkira Wiberg
Jan 17, 2015·Oncoscience·Yuanjie HuYi-Hong Zhou
Oct 22, 2013·Oncology Reports·Shun XuXin Zhang
Oct 21, 2020·Journal of Cellular Physiology·Heng Wee TanAndy T Y Lau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.